**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**Centre for Health Technology Evaluation**

# Technology Appraisal (Committee C) meeting minutes

**Minutes:** Confirmed

**Date and Time:** Wednesday 22 January 2020 at 10am

## Committee Members Present:

Stephen O’Brien (Chair) Present for all notes

Andrea Manca Present for all notes

Andrew Renehan Present for notes 1 to 9.6

David Foreman Present for all notes

Derek Ward Present for all notes

John Hampson Present for all notes

Matt Stevenson Present for all notes

Michael Chambers Present for all notes

Mona Johnson Present for all notes

Mudasar Mushtaq Present for all notes

Natalie Hallas Present for all notes

Nigel Langford Present for all notes

Paul Tappenden Present for all notes

Prithwiraj Das Present for all notes

Richard Nicholas Present for all notes

Rob Forsyth Present for all notes

Stella O’Brien Present for all notes

Ugochinyere Nwulu Present for all notes

## NICE Staff Present:

Helen Knight, Programme Director Present for all notes

Linda Landells, Associate Director Present for notes 1 to 7

Jasdeep Hayre, Associate Director Present for notes 8 to 17

Louise Jafferally, Project Manager Present for all notes

Pratit Shah, Administrator Present for all notes

Vicki Pollitt, Technical Analyst Present for notes 1 to 7

Caron Jones Technical Adviser Present for notes 1 to 7

Joel Russell, Technical Analyst Present for notes 8 to 12

Sally Doss, Technical Adviser Present for notes 8 to 12

Verena Wolfram, Technical Analyst Present for notes 13 to 17

Christian Griffiths, Technical Adviser Present for notes 13 to 17

## Non-public observers present:

Jonathan Shepherd, ERG representative Present for notes 1 to 4.7

Joanne Lord, ERG representative Present for notes 1 to 4.7

Olu Onyimadu, ERG representative Present for notes 1 to 4.7

Rob Riemsma, ERG representative Present for notes 8 to 9.6

Thea Van Asselt, ERG representative Present for notes 8 to 9.6

Lindsay Claxton, AG representative Present for notes 13 to 14.2

Matt Walton, AG representative Present for notes 13 to 14.2

Peter Clark, CDF clinical lead Present for notes 1 to 7

Tom Waddell , Clinical expert Present for notes 1 to 4.7

Balaji Venugopal, Clinical expert Present for notes 1 to 4.7

Kim Linton, Clinical expert Present for notes 8 to 9.6

Andrew Pettitt, Clinical expert Present for notes 8 to 9.6

Susanna Smith, Patient expert Present for notes 1 to 4.7

Michael Lee, Patient expert Present for notes 1 to 4.7

Peter Loftus, Patient expert Present for notes 8 to 9.6

Susan Jones, Patient expert Present for notes 8 to 9.6

Nicky Tyson, NICE observer Present for all notes

Katy Harrison, NICE observer Present for all notes

Claire Hawksworth, NICE observer Present for all notes

Sarah Bromley, NICE observer Present for all notes

Leslie Hayes, NICE observer Present for all notes

Charlotte Downing, NICE observer Present for all notes

Ewa Rupniewska, NICE observer Present for notes 1 to 12

Joel Russell, NICE observer Present for notes 1 to 7

Ella Fitzpatrick, NICE observer Present for notes 1 to 7

Thomas Strong, NICE observer Present for notes 1 to 7

Vicki Pollit, NICE observer Present for notes 8 to 12

Henry Cass, NICE observer Present for notes 13 to 17

## Notes

### Any other Business

1. None

### Minutes from the last meeting

1. The committee approved the minutes of the committee meeting held on Thursday 5 December 2019

## Appraisal of Pembrolizumab with axitinib for untreated advanced renal cell carcinoma [ID1426]

### Part 1 – Open session

1. The Chair welcomed the invited clinical and patient experts, Evidence Review Group (ERG) representatives and representatives from Merck Sharp & Dohme Pharmaceuticals
2. The Chair asked all committee members, experts, ERG and NICE staff present to declare any relevant interests

	1. Richard Nicholas declared a non-personal non-specific financial interest as he has provided work for a comparator company, Novartis Pharmaceuticals in an unrelated disease area.
		1. It was agreed that this declaration would not prevent Richard Nicholas from participating in this section of the meeting.
	2. Prithwiraj Das declared a non-personal non-specific financial interest as he works in Market Access at Boehringer Ingelheim on products in an unrelated disease area.
		1. It was agreed that this declaration would not prevent Prithwiraj Das from participating in this section of the meeting.
	3. Balaji Venugopal declared the following interests: A non-personal specific financial interest as he is a member of an advisory board for Bristol Myers & Squibb Pharmaceuticals, EUSA Pharma and Merck Sharp & Dohme. A non-personal specific financial interest as he is a principal investigator in clinical trials sponsored by Merck Sharp & Dohme, Ipsen and Pfizer.
		1. It was agreed that the declarations would not prevent Balaji Venugopal from participating in this section of the meeting.
	4. Tom Waddell declared the following interests: A non-personal specific financial interest as he acted as an clinical advisor to the Evidence Review Group, Liverpool Reviews & Implementation group and he provided advise on reviewing a company submission based on the combination of Avelumab and Axitinib. A non-personal specific financial interest as he received a research grant and consultancy fee funded by Merck Sharp & Dohme.
		1. It was agreed that declarations would not prevent Tom Waddell from participating in this section of the meeting.
	5. Susanna Smith declared a non-personal specific non-financial interest as she was involved in supporting recent clinical trial studies using kidney cancer drugs.
		1. It was agreed that this declaration would not prevent Susanna Smith from participating in this section of the meeting.
	6. Michael Lee declared a personal specific non-financial interest as he participated as a patient in clinical trial studies using Pembrolizumab with axitinib.
		1. It was agreed that this declaration would not prevent Michael Lee from participating in this section of the meeting.
	7. No further conflicts of interest were declared for this appraisal.

### Part 2 – Closed session (company representatives, clinical and patient experts, ERG and members of the public were asked to leave the meeting)

1. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) was discussed by the committee.
2. The committee decision was based on consensus.
3. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.

## Appraisal of Lenalidomide with rituximab for previously treated follicular lymphoma [ID1374]

### Part 1 – Open session

1. The Chair welcomed the invited clinical and patient experts, Evidence Review Group (ERG) representatives and representatives from Celgene Ltd.
2. The Chair asked all committee members, experts, ERG and NICE staff present to declare any relevant interests

	1. Michael Chambers declared a non-personal non-specific financial interest as he provided consultancy advice to a comparator company, Roche Products in an unrelated disease area.
		1. It was agreed that this declaration would not prevent Michael Chambers from participating in this section of the meeting.
	2. Prithwiraj Das declared a non-personal non-specific financial interest as he works in Market Access at Boehringer Ingelheim on products in an unrelated disease area.
		1. It was agreed that this declaration would not prevent Prithwiraj Das from participating in this section of the meeting.
	3. Andrea Manca declared a non-personal specific financial interest as he is a CI investigator in follicular lymphoma related projects funded by the National Institute of Health Research and the European Union.
		1. It was agreed that this declaration would not prevent Andrea Manca from participating in this section of the meeting.
	4. Andrew Pettitt declared the following interests: A non-personal specific financial interest as he is a Lead Investigator in follicular lymphoma at the National Cancer Research Institute. A non-personal specific financial interest as he has received consultancy fees from Roche Products and Celgene.
		1. It was agreed that this declaration would not prevent Andrew Pettitt from participating in this section of the meeting.
	5. Kim Linton declared the following interests: A non-personal specific financial interest as she is part of an advisory board on Indolent NHL funded by Celgene Ltd. A non-personal specific financial interest as she is Chair of the National Cancer Research Institute for clinical studies in low grade lymphoma subgroups
		1. It was agreed that this declaration would not prevent Kim Linton from participating in this section of the meeting
	6. No further conflicts of interest were declared for this appraisal.

### Part 2 – Closed session (company representatives, clinical and patient experts, ERG representatives and members of the public were asked to leave the meeting)

1. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) was discussed by the committee.
2. The committee decision was based on consensus.
3. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.

## Appraisal of Selective internal radiation therapies (SIRT) for treating hepatocellular carcinoma [ID1276]

### Part 1 – Open session

1. The Chair welcomed the invited clinical and patient experts, Assessment Group (AG) representatives and representatives from BTG International, Terumo europe, Sirtex Medical.
2. The Chair asked all committee members, experts, AG representatives and NICE staff present to declare any relevant interests

	1. Prithwiraj Das declared a personal specific financial interest which was reviewed by the associate director for this appraisal.
		1. It was agreed that this declaration would not prevent Prithwiraj Das from participating in this section of the meeting.
	2. No further conflicts of interest were declared for this appraisal.

### Part 2 – Closed session (company representatives, clinical and patient experts, AG representatives and members of the public were asked to leave the meeting)

1. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) was discussed by the committee.
2. The committee decision was based on consensus.
3. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.

## Next committee meeting:

**Tuesday 18 February 2020 at 10am**.The meeting will be held at Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BT, United Kingdom